Endocrine Abstracts

Background: Oestrogen can increase bone mineral density (BMD) by decreasing bone turnover, which is mainly seen in trabecular bone. Testosterone can increase bone size, but the effect on BMD is less clear. Cross-sex hormonal treatment (CSHT) in transsexuals can therefore affect the BMD. For example, in male-to-female individuals (MtFs) a lower BMD before start of CSHT has been described in comparison to healthy control men.Objectives: To investigate the ...

Introduction: Cross-sex hormone therapy is part of the treatment of individuals with gender dysphoria and affects several factors such as body composition and thereby cardiovascular risk. However, little is known about the specific effects on body weight and fat percentage in the first year of treatment.Aim: The aim of this study is to examine the effects of cross-sex hormones on body weight and total fat percentage during the first year of treatment.</p...

Background: Concerns about the effects of gender affirming hormonal treatment (HT) on bone mineral density (BMD) exists, particularly for transmen with decreasing estrogen levels. HT in transpersons affects BMD on short term, but long-term follow-up studies are lacking. Therefore this study aimed to investigate the change in BMD during the first 10 years of HT in adult transwomen and transmen, in order to determine whether it is necessary to assess BMD during HT.<p class="...

Introduction: Estrogen has positive effects on bone mineral density (BMD), in particular in trabecular bone through inhibition of bone resorption. Testosterone increases bone size, but the effect on BMD is less clear. Cross-sex hormonal treatment (CSHT) in transgender individuals can affect BMD. Therefore, the aim of this study is to investigate effects of CSHT on BMD during the first year of treatment in male-to-female (MtFs) and female-to-male (FtMs) transgender persons....